tepotinib
merck
['nsclc', 'tepotinib', 'sclc']
this large nonrandomized clinical trial of patients with met exon 14 skipping nsclc supports global approvals of tepotinib, enabling clinicians to implement optimal therapeutic approaches. #asco23 
JAMA #Oncology is an international peer-reviewed journal and the definitive journal for scientists, clinicians, and trainees in the field of oncology.